Salvo Health announced it has raised $8.5 million in Series A funding to accelerate the expansion of its hybrid gastrointestinal and metabolic care platform, a model designed to help GI practices deliver more continuous, outcomes-driven care while improving the patient experience and strengthening practice economics. The Series A was led by ManchesterStory, City Light Capital, and Threshold Ventures. Salvo said the funding will be used to help GI practices implement technology-enabled, continuous care capabilities and to scale what it describes as a provider-first model.
The company said the new financing will support broader adoption of its AI-enhanced approach, which is built to extend care beyond traditional, episodic appointments and into ongoing, day-to-day management for patients with chronic conditions.
The company’s positioning emphasizes working alongside existing GI practices rather than replacing them, and it offers infrastructure to support longitudinal care, multidisciplinary coordination, and proactive patient engagement.
Salvo highlighted strong momentum through 2025, reporting 800% year-over-year growth in both patients and revenue. The company also said it partnered with 801 GI providers, which it estimates represents roughly 16% of independent gastroenterologists in the U.S. In addition, Salvo reported signing three of the four largest GI practices nationwide, suggesting traction with large-scale operators and a path to rapid scaling through practice partnerships.
The company’s hybrid model sits at the intersection of GI care and metabolic health, reflecting the reality that many chronic gastrointestinal conditions overlap with broader metabolic concerns and require more than periodic specialist visits to manage effectively. Salvo’s approach aims to support patients over time through structured programs and continuous touchpoints, while enabling practices to offer care that is more responsive and comprehensive. By incorporating AI-enhanced workflows, the platform is intended to help practices manage larger patient panels, identify issues earlier, and deliver care more consistently without placing additional strain on already busy clinical teams.
Salvo said its strategy is focused on building a scalable system that improves outcomes, expands access to multidisciplinary care, and increases revenue for provider groups. The company framed the opportunity around the large and growing population of patients living with chronic GI and metabolic conditions, arguing that these patients benefit from continuous management rather than one-off interventions. With the new funding, Salvo plans to deepen adoption among GI practices and continue developing its hybrid care model as a long-term infrastructure layer for specialty care delivery.
